Kidney Medication Safety Directory

NSAIDs like ibuprofen reduce blood flow to the kidneys and can cause acute kidney injury, especially in people with existing kidney disease, dehydration, or who take blood pressure medications. Regular use is a leading cause of medication-related kidney damage.

Like all NSAIDs, naproxen reduces blood flow to the kidneys and can cause kidney damage, fluid retention, and elevated blood pressure. Particularly dangerous for people with CKD stages 3-5.

High-dose aspirin (>1000mg/day) has NSAID-like effects on the kidneys. Low-dose aspirin (81mg) for heart protection is generally safe for most kidney patients when prescribed by their doctor.

Acetaminophen is generally considered the safest pain reliever for people with kidney disease. It does not affect kidney blood flow like NSAIDs. However, it should be used at the lowest effective dose.

While somewhat safer than traditional NSAIDs, celecoxib still carries kidney risks including reduced blood flow, fluid retention, and potential kidney damage. Use with caution and medical supervision.

ACE inhibitors like lisinopril are actually kidney-protective for most CKD patients. They reduce pressure inside the kidneys and slow CKD progression. They may cause a small, expected rise in creatinine (up to 30%).

ARBs like losartan, similar to ACE inhibitors, are kidney-protective. They reduce proteinuria and slow CKD progression. First-line treatment for CKD patients with hypertension or proteinuria.

Calcium channel blockers like amlodipine are safe for kidney patients. They effectively lower blood pressure without significant kidney side effects.

Thiazide diuretics may be less effective when eGFR drops below 30. They can cause electrolyte imbalances (low potassium, sodium). Generally safe in earlier CKD stages with monitoring.

Loop diuretics like furosemide help manage fluid retention in CKD but require careful monitoring. They can cause dehydration and electrolyte imbalances if not properly dosed.

Metformin is safe for most diabetic patients with eGFR above 30. Below eGFR 30, there's a risk of lactic acidosis and it should be stopped. Dose reduction may be needed between eGFR 30-45.

SGLT2 inhibitors like empagliflozin have shown kidney-protective benefits in clinical trials. They slow CKD progression and reduce hospitalization for heart failure. Recommended by KDIGO for diabetic kidney disease.

Long-term PPI use (over 1 year) has been associated with increased risk of chronic kidney disease and acute interstitial nephritis in some studies. Short-term use is generally safe.

Amoxicillin is generally safe for kidney patients. Dose adjustment may be needed in advanced CKD (eGFR <30) to prevent accumulation.

Fluoroquinolones require dose adjustment in kidney disease. They can crystallize in the kidneys if not well-hydrated. Generally usable with proper dosing.

Aminoglycoside antibiotics like gentamicin are directly toxic to kidney cells (nephrotoxic). They can cause acute kidney injury even in people with normal kidneys. Use only when absolutely necessary with close monitoring.

High-dose vitamin C (>500mg/day) can increase oxalate levels, raising the risk of kidney stones. It can also accumulate in kidney disease and cause oxalate nephropathy.

Magnesium is excreted by the kidneys. In advanced CKD, magnesium can accumulate to dangerous levels, causing muscle weakness, low blood pressure, and heart rhythm problems.

Potassium supplements are dangerous for people with kidney disease. Kidneys with reduced function cannot excrete excess potassium, leading to hyperkalemia (high potassium), which can cause life-threatening heart rhythm problems.

Calcium supplements may increase the risk of vascular calcification in CKD patients, especially when combined with low vitamin D levels. They can also increase kidney stone risk.

Vitamin D deficiency is very common in CKD. Supplementation is often recommended and can help with bone health and immune function. Active forms (calcitriol) may be prescribed in advanced CKD.

Iron supplementation is commonly needed in CKD to treat anemia. Oral iron is safe, though IV iron may be more effective in advanced CKD. Side effects include constipation and stomach upset.

Pseudoephedrine and phenylephrine can raise blood pressure significantly, which is harmful for kidney patients. They can also interact with blood pressure medications.

Aluminum-containing antacids can cause aluminum toxicity in kidney disease because the kidneys cannot excrete aluminum efficiently. This can lead to bone disease and neurological problems.

H2 blockers like famotidine are generally safe for kidney patients. Dose adjustment may be needed in advanced CKD. A good alternative to PPIs for acid reflux.

Diphenhydramine can accumulate in kidney disease and cause excessive sedation, confusion, and urinary retention. Generally safe at low doses but use with caution.

Creatine supplements can artificially raise serum creatinine levels, making kidney function appear worse than it is. There's ongoing debate about whether creatine actually damages kidneys, but it should be avoided with existing CKD.

Many herbal supplements are not well-studied for kidney safety. Some (like aristolochic acid, found in some traditional medicines) are directly nephrotoxic. Others may interact with medications or contain potassium/phosphorus.

Allopurinol is used to treat gout and is generally safe for kidney patients with dose adjustment. It may actually have kidney-protective effects by reducing uric acid levels.

Gabapentin is cleared by the kidneys and accumulates in CKD. Dose must be significantly reduced based on eGFR. Accumulation can cause sedation, dizziness, and confusion.

Like gabapentin, pregabalin is renally cleared and accumulates in CKD. Dose adjustment is essential based on creatinine clearance.

SGLT2 inhibitor shown to slow CKD progression in the landmark DAPA-CKD trial. Now recommended by KDIGO for CKD patients even without diabetes.

SGLT2 inhibitor with kidney-protective benefits shown in the CREDENCE trial. Reduces progression of diabetic kidney disease.

Insulin is safe for kidney patients. However, insulin clearance decreases as kidney function declines, which may increase the risk of hypoglycemia (low blood sugar).

Sulfonylurea that is metabolized by the liver, making it safer for kidney patients than glyburide. Used for type 2 diabetes when metformin is contraindicated.

Glyburide has active metabolites that accumulate in kidney disease, causing prolonged and dangerous hypoglycemia (low blood sugar).

GLP-1 receptor agonist that is safe for kidney patients. Some evidence suggests potential kidney-protective effects. No dose adjustment needed for CKD.

GLP-1 receptor agonist safe in kidney disease. The LEADER trial showed cardiovascular benefits. No dose adjustment needed.

Thiazolidinedione that is liver-metabolized but can cause fluid retention, which is problematic in CKD with edema.

ACE inhibitor with kidney-protective properties. Reduces proteinuria and slows CKD progression. First-line for CKD with proteinuria.

ACE inhibitor shown in the HOPE trial to reduce cardiovascular events. Kidney-protective benefits similar to other ACE inhibitors.

ARB with kidney-protective effects. Used when ACE inhibitors cause cough. Do not combine with ACE inhibitors.

ARB specifically studied in diabetic kidney disease (IDNT trial). Proven to slow progression of diabetic nephropathy.

Beta-blocker safe for kidney patients. Liver-metabolized so no dose adjustment needed in CKD. Good for heart rate control.

Beta-blocker that is renally cleared. Accumulates in kidney disease and may cause excessive heart rate slowing and fatigue.

Combined alpha/beta-blocker. Liver-metabolized so safe in CKD. Particularly useful for heart failure with CKD.

Potassium-sparing diuretic. Can cause dangerous hyperkalemia (high potassium) in CKD, especially when combined with ACE inhibitors or ARBs.

Central-acting antihypertensive safe in CKD. Useful as add-on therapy when blood pressure is difficult to control.

Non-dihydropyridine calcium channel blocker. Safe in CKD and may help reduce proteinuria when used with ACE inhibitors/ARBs.

Direct vasodilator. Safe in CKD and useful as add-on therapy for resistant hypertension.

Statins are safe and recommended for many CKD patients to reduce cardiovascular risk, which is elevated in CKD. Liver-metabolized.

Potent statin safe in CKD. The SHARP trial showed benefits for CKD patients. Higher doses may need adjustment in severe CKD.

Combined with ezetimibe in the SHARP trial for CKD patients. Safe and effective for cholesterol management.

Cholesterol absorption inhibitor. Safe in CKD. Often combined with statins for additional LDL reduction.

Tetracycline antibiotic that is liver-metabolized, making it safe for kidney patients. No dose adjustment needed in CKD.

Macrolide antibiotic that is hepatically cleared. Safe in CKD without dose adjustment needed.

Nitrofurantoin is ineffective and potentially toxic when eGFR is below 30. The drug doesn't concentrate in urine with poor kidney function, making it useless for UTIs.

Can cause hyperkalemia and interfere with creatinine measurement (making eGFR appear lower). Dose adjustment needed in CKD.

IV vancomycin requires careful dosing and monitoring in CKD. Nephrotoxic at high trough levels. Drug level monitoring is essential.

Antifungal that requires dose reduction in CKD. Renally cleared so accumulates with reduced kidney function.

Can crystallize in renal tubules if patient is dehydrated. Dose must be adjusted in CKD. Adequate hydration during treatment is essential.

CKD patients on warfarin have higher bleeding risk. Kidney disease affects warfarin metabolism and response. More frequent INR monitoring needed.

DOAC with the least renal clearance (~27%), making it the preferred DOAC in CKD. May need dose reduction in advanced CKD.

DOAC that is partially renally cleared (~33%). Avoid when eGFR is below 15. Dose adjustment may be needed.

Primarily renally cleared (~80%). Contraindicated in severe CKD (eGFR < 30). Accumulation increases bleeding risk dramatically.

Antiplatelet medication that is liver-metabolized. Safe in CKD without dose adjustment.

SSRI antidepressant that is liver-metabolized. Safe in CKD. Depression is common in CKD patients and should be treated.

SSRI that is hepatically cleared. Safe for kidney patients. Depression can worsen CKD outcomes if untreated.

SNRI used for depression and neuropathic pain. Active metabolites may accumulate in severe CKD. Avoid if eGFR < 30.

Long-term lithium use can cause chronic kidney disease (lithium nephropathy). Requires close monitoring of kidney function and lithium levels.

Benzodiazepine that is hepatically cleared with no active metabolites. Preferred benzodiazepine in CKD.

Has active metabolites that accumulate in CKD, causing prolonged sedation. Lorazepam is preferred.

Opioid-like pain medication that is renally cleared. Dose must be significantly reduced in CKD. Risk of seizures increases with accumulation.

Active metabolite (M6G) accumulates in CKD, causing respiratory depression and excessive sedation that can be life-threatening.

Preferred opioid for CKD patients as it has no active renal metabolites. Still requires dose adjustment and monitoring.

Active metabolites accumulate in CKD, causing excessive sedation and respiratory depression. Should be avoided.

Used for gout flares. Dose must be reduced in CKD as it's partially renally cleared. Can cause toxicity with accumulation.

Xanthine oxidase inhibitor for chronic gout. Hepatically metabolized so safe in CKD. Alternative to allopurinol.

Corticosteroid that is safe for short-term use but long-term use can worsen diabetes, blood pressure, and bone health , all concerns in CKD.

Renally cleared drug that can cause severe toxicity in CKD including bone marrow suppression and mucositis. Also directly nephrotoxic at high doses.

Immunosuppressant used in kidney transplant that is paradoxically nephrotoxic. Requires careful therapeutic drug monitoring.

Standard immunosuppressant for kidney transplant. Nephrotoxic and requires careful monitoring of trough levels and kidney function.

Immunosuppressant used in kidney transplant and autoimmune kidney diseases. Not directly nephrotoxic.

ESA (erythropoiesis-stimulating agent) used to treat anemia of CKD. Stimulates red blood cell production to replace the EPO kidneys can no longer make.

Phosphorus binder that reduces phosphorus absorption from food. Non-calcium-based, preferred over calcium-based binders in many CKD patients.

Used to treat metabolic acidosis in CKD. Helps maintain blood pH balance. May slow CKD progression.

Potassium binder used to treat hyperkalemia in CKD. Allows patients to continue taking ACE inhibitors/ARBs that might otherwise be stopped.

Newer potassium binder for hyperkalemia in CKD. Fast-acting. Enables continued use of RAAS inhibitors.

Non-calcium phosphorus binder. Chewing tablets taken with meals to reduce phosphorus absorption.

Used to treat secondary hyperparathyroidism in CKD and dialysis. Lowers parathyroid hormone, calcium, and phosphorus levels.

Anti-seizure medication with protein binding that changes in CKD, making drug levels unpredictable. Free drug levels should be monitored.

Renally cleared anti-seizure medication. Dose must be adjusted based on kidney function.

Non-sedating antihistamine that is liver-metabolized. Safe for kidney patients without dose adjustment.

Antihistamine safe in CKD. May need dose reduction in advanced CKD. Less sedating than diphenhydramine.

Anti-diarrheal that works locally in the gut. Safe for occasional use in CKD. Does not significantly affect kidney function.

Contains salicylate (aspirin-like compound) and bismuth, both of which can accumulate in CKD. Can worsen kidney function and cause toxicity.

Can cause severe and potentially fatal hyperphosphatemia and acute kidney injury in CKD patients. Multiple fatalities reported.

Osmotic laxative that is safe for kidney patients. Does not significantly affect electrolytes or kidney function.

Stool softener that is safe for kidney patients. Works by increasing water content of stool.

Magnesium accumulates in CKD and can cause hypermagnesemia , muscle weakness, hypotension, respiratory depression, and cardiac arrest.

Omega-3 fatty acids are safe for kidney patients. May have anti-inflammatory benefits. Some evidence of cardiovascular benefit in CKD.

Generally safe for kidney patients. Some research suggests probiotics may help reduce uremic toxins in CKD.

Often recommended for CKD patients, especially those on dialysis. Water-soluble B vitamin that may be depleted in CKD.

Water-soluble B vitamins are depleted in CKD, especially with dialysis. Renal-specific formulas avoid excess vitamin A.

Standard multivitamins may contain excess vitamin A (which accumulates in CKD), potassium, and phosphorus. Use renal-specific formulations instead.

Iodinated contrast used in CT scans and angiograms can cause contrast-induced nephropathy, especially with eGFR below 30. Risk is highest with large volumes and dehydration.

Finerenone is a breakthrough nonsteroidal selective mineralocorticoid receptor antagonist (nsMRA). Proven in the FIDELIO-DKD and FIGARO-DKD clinical trials to significantly slow CKD progression and reduce cardiovascular events in patients with CKD associated with type 2 diabetes. Unlike traditional MRAs, it has a lower risk of severe hyperkalemia while providing robust renal protection.

Dual GIP and GLP-1 receptor agonist that improves glycemic control and facilitates substantial weight reduction. Hepatically metabolized through proteolytic cleavage, meaning it does not rely on renal excretion. SURPASS-4 trial secondary analyses demonstrated significant reductions in albuminuria and slower decline in eGFR compared to insulin.

Prescription nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed for arthritis. Like all NSAIDs, meloxicam inhibits renal cyclooxygenase (COX-1 and COX-2) enzymes, halting the production of vasodilating prostaglandins. This causes acute vasoconstriction of the afferent renal arterioles, directly lowering glomerular filtration and precipitating acute kidney injury.

Potent NSAID available in oral formulations and topical gels. Systemic absorption from oral pills significantly reduces renal blood flow and can trigger acute interstitial nephritis, papillary necrosis, or accelerated CKD progression. Topical gel formulations have substantially lower systemic absorption (roughly 6%) but should still be used cautiously in advanced CKD.

Extremely potent injectable and oral NSAID with severe nephrotoxic potential. Ketorolac is one of the most hazardous drugs for kidney patients and is a leading medical cause of hospital-acquired acute tubular necrosis and acute renal failure. Even a single dose can cause severe decline in kidney function in people with borderline renal reserves.

Potent traditional NSAID historically prescribed for acute gout attacks and pericarditis. It is among the most potent inhibitors of renal prostaglandins, carrying an exceptionally high risk of abrupt renal failure, severe sodium/water retention, blunting of antihypertensive therapies, and life-threatening hyperkalemia in CKD patients.

Proton pump inhibitor (PPI) widely prescribed for acid reflux, GERD, and ulcer prophylaxis. While effective for gastric acid suppression, large observational cohort studies have demonstrated an independent association between long-term PPI therapy and increased risks of acute interstitial nephritis (AIN), CKD progression, and hypomagnesemia.

S-isomer of omeprazole used for severe acid reflux and erosive esophagitis. Similar to other proton pump inhibitors, chronic daily use beyond 8-12 weeks has been epidemiologically linked with increased incidence of chronic kidney disease and tubulointerstitial injury. Short-term treatment for active ulceration remains medically appropriate.

First-generation H2 blocker that competitively inhibits the organic cation transporter (OCT2) in the proximal renal tubules. Because it blocks the active tubular secretion of creatinine into urine, cimetidine causes a benign, artificial rise in blood serum creatinine without actually decreasing true glomerular filtration rate (GFR).

Dipeptidyl peptidase-4 (DPP-4) inhibitor that is uniquely excreted primarily through the biliary and hepatointestinal tract (only ~5% eliminated renally). As established in the CARMELINA trial, linagliptin is the only oral DPP-4 inhibitor that requires zero dose adjustment across all stages of CKD, including stage 5 and hemodialysis.

Widely prescribed oral DPP-4 inhibitor for type 2 diabetes. Unlike linagliptin, sitagliptin is primarily eliminated by the kidneys (approximately 79% excreted unchanged in urine). As kidney function declines, the drug accumulates, significantly increasing exposure and side effect risks unless the daily dosage is appropriately reduced based on eGFR.

Second-generation sulfonylurea used to treat type 2 diabetes. Glimepiride is metabolized into active metabolites (including M1) that depend on renal elimination. In patients with CKD, these active metabolites accumulate dramatically, leading to severe, unpredictable, and prolonged hypoglycemia that can require prolonged hospitalization.

Once-weekly GLP-1 receptor agonist for type 2 diabetes. In the AWARD-7 clinical trial, dulaglutide demonstrated significant renal protection, preserving eGFR and substantially decreasing urine albumin-to-creatinine ratio (uACR) in patients with moderate-to-severe CKD. Because it is broken down into small peptides by general protein catabolism, it does not rely on renal clearance.

High-potency loop diuretic commonly prescribed for edema, fluid overload, and hypertension in CKD and congestive heart failure. Torsemide offers superior, more predictable oral bioavailability (80-90%) and a longer duration of action compared to furosemide, making it an excellent agent for diuretic resistance in advanced kidney disease.

Extremely potent loop diuretic, approximately 40 times more potent milligram-for-milligram than furosemide. Used extensively in nephrology when patients develop resistance to other diuretics or suffer severe fluid retention in CKD stages 4-5 and nephrotic syndrome.

Long-acting thiazide-like diuretic with a prolonged half-life of 40 to 60 hours. While older guidelines claimed thiazides fail when eGFR is under 30, the landmark CLICK trial (published in the New England Journal of Medicine) conclusively demonstrated that chlorthalidone effectively lowers blood pressure and reduces albuminuria even in stage 4 CKD.

Angiotensin II receptor blocker (ARB) with unique pharmacological properties, including a long 24-hour half-life and partial PPAR-gamma agonism. In clinical trials such as ONTARGET and TRANSCEND, telmisartan demonstrated powerful kidney-protective and cardiovascular benefits, effectively reducing proteinuria in hypertensive kidney disease.

ACE inhibitor frequently utilized in renal clinics for kidney protection. The landmark Hou et al. trial published in the NEJM established that benazepril provides substantial renal protection and slows the progression of non-diabetic advanced renal disease even in patients with serum creatinine up to 5.0 mg/dL (CKD stages 3b-4).

Potent ARB that provides strong 24-hour blood pressure reduction and significant decreases in microalbuminuria. Effective for hypertensive renal disease. Patients should be aware of a rare, specific adverse reaction called sprue-like enteropathy (severe chronic diarrhea with weight loss), which resolves upon discontinuing the drug.

Selective mineralocorticoid receptor antagonist (MRA) that blocks aldosterone without the hormonal side effects (gynecomastia) of spironolactone. Used for resistant hypertension, proteinuric CKD, and post-myocardial infarction heart failure. Because it prevents potassium excretion in the collecting duct, hyperkalemia risk is significant in CKD.

Chewable, non-calcium, iron-based phosphate binder formulated specifically for patients with chronic kidney disease on dialysis. Each chewable tablet binds dietary phosphorus in the gastrointestinal tract with minimal iron absorption, allowing patients to control hyperphosphatemia with a significantly lower daily pill burden compared to sevelamer.

Dual-action oral iron-based medication FDA-approved for two distinct CKD indications: controlling serum phosphorus in adults with CKD on dialysis, and treating iron-deficiency anemia in adults with non-dialysis dependent CKD (stages 3-5). It binds gut phosphorus while releasing bioavailable iron that increases ferritin and transferrin saturation.

Calcium-based phosphate binder used to reduce dietary phosphorus absorption in end-stage renal disease. While inexpensive and effective, calcium-containing binders can contribute to positive calcium balance and accelerate vascular and cardiac calcification in CKD patients, particularly if serum calcium is already normal or high.

Intravenous calcimimetic agent administered three times per week at the conclusion of hemodialysis. It binds directly to and activates the calcium-sensing receptor on the parathyroid gland, suppressing parathyroid hormone (PTH) secretion and controlling secondary hyperparathyroidism without requiring daily oral pills.

First-in-class selective peripherally acting kappa opioid receptor (KOR) agonist FDA-approved for the treatment of moderate-to-severe chronic kidney disease-associated pruritus (intractable uremic itching) in adults undergoing hemodialysis. It works on peripheral sensory nerves and immune cells without entering the central nervous system.

First-generation cephalosporin antibiotic widely prescribed for skin, soft tissue, and urinary tract infections. Cephalexin is eliminated almost entirely by glomerular filtration and tubular secretion in the kidneys. In CKD, the drug's half-life increases from 1 hour up to 8 hours, requiring extended dosing intervals to prevent drug accumulation.

Third-generation cephalosporin antibiotic used for respiratory tract and ear infections. Primarily excreted by the kidneys. In patients with creatinine clearance below 30 mL/min, drug clearance is significantly reduced, necessitating a 50% dose reduction to maintain safe blood concentrations.

Potent fluoroquinolone antibiotic used for serious bacterial infections. Approximately 87% of levofloxacin is excreted unchanged in the urine. Because of this high renal dependence, failure to reduce the dose in CKD leads to toxic accumulation, substantially increasing risks of CNS toxicity, seizures, tendon rupture, and crystal nephropathy.

Combination penicillin antibiotic and beta-lactamase inhibitor. Both amoxicillin and clavulanic acid are excreted primarily by the kidneys. While safe at modified doses, standard high-dose formulations (such as 875mg twice daily or 1000mg extended release) should be avoided in severe CKD due to accumulation.

Combination opioid analgesic (hydrocodone) and non-opioid pain reliever (acetaminophen). Safer than NSAIDs for kidney patients because it does not compromise renal blood flow. However, hydrocodone elimination is prolonged in CKD, which can lead to sedation and respiratory depression if doses are taken too frequently.

Potent semi-synthetic opioid. In healthy individuals, oxycodone and its active metabolites are eliminated in the urine. In patients with renal impairment, clearance of both the parent drug and metabolites decreases by roughly 50%, prolonging sedation, central nervous system depression, and constipation.

Long-acting synthetic opioid primarily metabolized by the liver via CYP3A4 and excreted through feces and bile (fecal elimination increases compensatory in renal failure). Because it produces no active renal metabolites, methadone is clinically considered one of the safest opioids in severe CKD and end-stage renal disease.

Extremely potent direct-acting peripheral vasodilator reserved for severe, refractory hypertension that fails to respond to multiple other medications in advanced CKD. Because it dilates peripheral arterioles dramatically, it prompts intense renal sodium and water retention and reflex tachycardia, requiring co-administration with high-dose loop diuretics and beta-blockers.

Selective alpha-1 adrenergic receptor blocker used to manage both hypertension and benign prostatic hyperplasia (BPH). Doxazosin undergoes extensive hepatic metabolism and is excreted almost entirely in feces (only ~5% excreted in urine), making it very safe for kidney patients without requiring dose adjustments.

5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), used to treat benign prostatic hyperplasia and male pattern hair loss. Finasteride is extensively metabolized by the liver, with less than 1% excreted in urine, making it exceptionally safe for patients across all stages of kidney disease.

Selective alpha-1A adrenergic antagonist widely prescribed for benign prostatic hyperplasia and off-label for facilitating the passage of small kidney stones. Extensively metabolized by liver cytochrome P450 enzymes. Safe in CKD without dosage adjustments, though patients with advanced CKD should monitor for orthostatic lightheadedness.

Phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction (Viagra) and pulmonary arterial hypertension (Revatio). Cleared mainly by hepatic metabolism, but severe renal impairment (eGFR < 30 mL/min) increases systemic exposure (AUC) by approximately 100%, necessitating lower starting doses.